CytomX Therapeutics Market Sentiment

SPY767.60−0.26%QQQ720.91−1.10%BTC/USD81,148.03−0.51%DIA517.33+0.33%GLD381.12+1.37%TLT80.04+1.46%

Premium

CytomX Therapeutics Inc

CTMXNASDAQ

Trade with Public

$2.23

-0.095-4.09%

Last update: Oct 15, 4:51 AM

$2.25

-0.0749-3.22%

Overview News Earnings Forecast Events Price Targets FinancialsSentimentOwnership Compare Stock Report

CytomX Therapeutics Market Sentiment - Benzinga

CytomX Therapeutics Market Sentiment

Market sentiment signals for CytomX Therapeutics (CTMX): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▼ 21.3% short float

Options Flow— N/A

Insider Activity— N/A

Analyst Consensus

Buy

11 analysts

Options Flow (P/C)

—

Avg Consensus PT

$11

+371.1%

Highest Price Target

$16

+611.1%

Jefferies

Lowest Price Target

+59.5%

BMO Capital

Short Interest

21.3%

Rising — Bearish

Insider Activity (30d)

—

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Aug 13, 2026	JP Morgan	Anupam Rama—	+388.9%	$12 → $11	Maintained	Overweight
Aug 10, 2026	Guggenheim	Michael Schmidt—	+522.2%	$15 → $14	Maintained	Buy
May 11, 2026	HC Wainwright & Co.	Mitchell S. Kapoor—	+388.9%	$17 → $11	Maintained	Buy
Mar 23, 2026	Piper Sandler	Joseph Catanzaro—	+433.3%	$10 → $12	Maintained	Overweight
Mar 19, 2026	Barclays	Etzer Darout—	+611.1%	$10 → $16	Maintained	Overweight
Mar 18, 2026	Jefferies	Roger Song—	+611.1%	$8 → $16	Maintained	Buy
Mar 18, 2026	Guggenheim	Michael Schmidt—	+566.6%	$10 → $15	Maintained	Buy
Mar 17, 2026	Wedbush	Robert Driscoll—	+388.9%	$6 → $11	Maintained	Outperform
Mar 16, 2026	HC Wainwright & Co.	Mitchell S. Kapoor—	+655.5%	$10 → $17	Maintained	Buy
Mar 16, 2026	JP Morgan	Anupam Rama—	+433.3%	$7 → $12	Upgrade	Neutral→Overweight
Mar 9, 2026	Guggenheim	Michael Schmidt—	+344.4%	$10 → $10	Maintained	Buy
Feb 4, 2026	Cantor Fitzgerald	Olivia Brayer—	+344.4%	$6 → $10	Maintained	Overweight
Feb 4, 2026	Barclays	Etzer Darout—	+344.4%	$8 → $10	Maintained	Overweight
Jan 20, 2026	Barclays	Etzer Darout—	+255.5%	$6 → $8	Maintained	Overweight
Jan 20, 2026	Guggenheim	Michael Schmidt—	+344.4%	$10	Initiate	Buy
Jan 20, 2026	Piper Sandler	Joseph Catanzaro—	+344.4%	$7 → $10	Maintained	Overweight
Nov 11, 2025	HC Wainwright & Co.	Mitchell S. Kapoor—	+344.4%	$5 → $10	Maintained	Buy
Oct 21, 2025	Barclays	Etzer Darout—	+166.7%	$4 → $6	Maintained	Overweight
Sep 22, 2025	Cantor Fitzgerald	Olivia Brayer—	+166.7%	$6	Initiate	Overweight
Sep 17, 2025	Barclays	Etzer Darout—	+55.5%	$4	Assumes	Overweight
Jul 31, 2025	Oppenheimer	Matthew Biegler—	+211.1%	$7	Initiate	Outperform
May 20, 2025	HC Wainwright & Co.	Mitchell Kapoor—	+122.2%	$5 → $5	Maintained	Buy
May 15, 2025	Piper Sandler	Joseph Catanzaro—	+122.2%	$3 → $5	Maintained	Overweight
May 15, 2025	HC Wainwright & Co.	Mitchell Kapoor—	+122.2%	$5 → $5	Upgrade	Neutral→Buy
Apr 14, 2025	Piper Sandler	Joseph Catanzaro—	+11.1%	$3 → $3	Maintained	Overweight